Merck (MRK) Liabilities from Discontinued Operations (2014 - 2020)
Merck (MRK) posted quarterly Liabilities from Discontinued Operations of 186000000.0 for Q4 2020, down 77.04% quarter-over-quarter from 810000000.0 in Q3 2014.
Merck (MRK) Liabilities from Discontinued Operations (2014 - 2020) Analysis & Trends
Merck (MRK) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 186000000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Liabilities from Discontinued Operations changed N/A year-over-year to 186000000.0; the TTM figure through Dec 2020 stood at 186000000.0 (changed N/A YoY), while the FY2020 annual figure was 186000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations eased to 186000000.0 in Q4 2020 per MRK's latest filing, from 810000000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 186000000.0 in Q4 2020 and bottomed at 186000000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 186.00 Mn |
| Dec 31, 2020 | 186.00 Mn |
| Sep 30, 2014 | 810.00 Mn |
| Sep 30, 2014 | 810.00 Mn |
| Jun 30, 2014 | 801.00 Mn |
| Jun 30, 2014 | 801.00 Mn |
| Mar 31, 2014 | 848.00 Mn |
| Mar 31, 2014 | 848.00 Mn |